Large Volume Parenteral Stoppers

Aptar Pharma's PureHale® Technology Platform is the first portable, pre-filled nebulizer –like device that, when used with saline or natural ingredient formulations, alleviates upper respiratory symptoms like coughs, colds, allergies, and dry nose and throat.

Aptar Pharma offers versatile and reliable Classic Line and VP6 spray pump technologies for multi-dose dispensing. Our modular solutions cater to diverse global markets, serving a wide range of products, from regulated prescriptions to over-the-counter and consumer health brands.

Aptar Pharma's Lyophilization Stoppers ensure stability and excellent performance during the freeze-drying process.

Aptar Pharma leads in elastomeric Rigid Needle Shields (RNS) for PFS and Auto-injector developments. Trusted by top manufacturers, we offer safe, high-quality solutions for injectables.

Aptar Pharma is a global leader in elastomeric Tip Caps, offering high-quality Pre-Filled Syringe components with unique rubber formulation for effective drug protection and safety in injectable developments. 

Aptar Pharma's Serum Stoppers offer optimal protection and drug delivery for blowback and non-blowback vials. 

Aptar Pharma is a global leader in elastomeric Plungers for Pre-Filled Syringes, providing safe and high-quality solutions for injectable developments.

AdhereIT® is a connected medical device that enhances patient adherence for self-injecting medication. It supports training and autoinjector devices, alleviating anxieties and promoting proper usage. Through multisensory feedback and app features, AdhereIT® enables patients to start treatment sooner an...

Noble's patient-centric training devices, mimic real drug delivery devices to improve self-administered therapies. They enhance patient experience, promote adherence, and boost health outcomes. These fully resettable and reusable devices offer a realistic drug delivery simulation, allowing patients to ...

PADA (Powder Administration Device for Animals) is a specialized kit by Aptar Pharma for pre-clinical pulmonary research. It allows precise and efficient powder delivery to mouse lungs, aiding early-stage drug development for asthma, COPD, lung cancers, and cystic fibrosis.

Aptar Digital Health is a leading provider of integrated health solutions and services. We offer a comprehensive range of patient-centric digital solutions that utilize our expertise and diverse product portfolio to deliver exceptional experiences and better outcomes.

At Aptar Pharma, we meet evolving dermal drug delivery needs, prioritizing patient safety and risk reduction. With the widest range of Airless devices, we support the increasing demand for dermal drug delivery solutions.

Aptar Pharma's presentation entitled "Innovations in Inhalation" explores the current extensive portfolio of high-quality OINDP (Orally Inhaled and Nasal Drug Products) delivery devices. The presentation also highlights Aptar Pharma's comprehensive services which support respiratory drug development, including device selection, formulation development, analytical methods, and regulatory support. A key focus of the talk is the introduction of Orbital, an innovative high payload DPI system designed to enhance drug delivery efficiency and patient compliance. This discussion aims to showcase Aptar Pharma's latest advancements in inhalation technology, emphasizing their commitment to improving patient care through innovative drug delivery systems.

Big Pharma reports that up to over 90% of their CO2 emissions are scope 3. This is not only a huge burden but also the most difficult part to influence for pharmaceutical industry. However, there are ways to manage and collaborate in the industry. Christophe Marie from Aptar Group will highlight how Aptar implemented specific targets with partners and suppliers to tackle the scope 3 challenge, coming from a consumer market perspective, extrapolating into the pharmaceutical business. Also, when talking about products we are increasingly facing requests to minimize our CO2 footprint in Pharma. A great example for collaborative approaches helping to de-risk and accelerate our clients’ low GWP pressurized Metered Dose Inhaler (pMDI) programs will be illustrated by Chris Baron, based on the transition of the current pMDIs to alternative low GWP propellant technologies. Join Christophe Marie and Chris Baron at CPHI to learn how Aptar Pharma supports more sustainable product

Aptar Pharma Brochure